[Deanol in tardive dyskinesia: a double-blind study (author's transl)].
Tardive dyskinesia following long-term application of neuroleptics is resistant to treatment. According to the hypothesis of a relative central nervous system acetylcholine lack as the underlying mechanism 20 patients were treated with dimethylaminoethanol (Deanol) in a double-blind study. Deanol is known to be a direct precursor of intracerebral acetylcholine. For several reasons (which are discussed) the data of but 11 patients were statistically evaluated. The results suggest some therapeutic effect in some of the patients only (significant improvement of oral hyperkinesia).
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003642:Deanol / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014149:Tranquilizing Agents / Q000009:adverse effects
D004983:Ethanolamines; D014149:Tranquilizing Agents; D003642:Deanol
Zur Therapie mit Dimethylaminoäthanol (Deanol) bei neuroleptikainduzierten extrapyramidalen Hyperkinesen